BI 3819026

DRUG2 trials

Sponsors

Takeuchi Yoshito, Boehringer Ingelheim

Conditions

Advanced Solid CancerMetastatic Solid Cancercolorectal cancer, non-small cell lung cancer, breast cancer, melanoma, hepatocellular carcinoma and

Phase 1

A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab

RecruitingJPRN-jRCT2031260026

Takeuchi Yoshitocolorectal cancer, non-small cell lung cancer, breast cancer, melanoma, hepatocellular carcinoma and

Start: 2026-04-20Target: 12Updated: 2026-06-29

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

RecruitingNCT07607678

Boehringer IngelheimAdvanced Solid Cancer, Metastatic Solid Cancer

Start: 2026-05-01End: 2030-10-15Target: 60Updated: 2026-08-04